In an exciting development for the field of biomedical innovation, NCC has been selected for the "Shanghai Science and Technology Innovation Action Plan" for 2024.

NCC is proud to announce that three of its innovative medical device products have been selected for the 2024 Shanghai Technology Innovation Action Plan.

On November 30, 2024, the NCC​ Electrophysiology marketing team gathered for a monthly meeting themed "Embracing the Present, Shaping the Future."

Recently, the "Shanghai Biomedical "New and Excellent Drugs and Devices" Product Catalog" (the fourth batch) was officially released, with a total of 51 products selected. Our company was approved for the Class III medical device certificate on July 2, 2024. It is the first domestically produced fully independently developed high-channel [32+256] "intraoperative nerve stimulation monitor" suitable for orthopedics and neurosurgery. Table of contents.

Shanghai, China – The Shanghai Municipal Science and Technology Commission has officially announced the public display of the "Shanghai Biopharmaceutical New and Excellent Medical Products Directory" (Fourth Batch).

On the afternoon of November 3, 2024, amidst the crisp autumn air, the marketing team at NCC gathered for their monthly meeting themed "All-Out Efforts, Bold Innovations." This meeting aimed to review the achievements of October, reflect on lessons learned, and set ambitious goals for the future.